Image For Activity Cover
Addiction Psychiatry Annual REVIEW: 2023 Highest Impact Publications
Abstract

This presentation provides an annual review of the highest impact peer-reviewed publications and newsmaker events across the field of Addiction Psychiatry from 2023. The goal of this session is to provide concise, critical summaries of the most important peer-reviewed publications and newsmaker events of the past year, organized using key topic areas such as addiction neurobiology, epidemiology, pharmacology, intoxication and withdrawal syndromes, screening and diagnosis, mutual help, harm reduction, dual diagnoses, and pharmacologic and behavioral interventions. We will provide more in-depth focus on a small, select group of articles that are high impact and likely to fundamentally change clinical practice. The Chairs and Presenters will survey the most prominent medical, psychiatric, and addiction journals as well as newsletters to select and rank recent articles by publication metrics (Journal Impact Factor, Most Downloaded and Most Viewed, and Altmetric scores), expert opinion, and topic focus. Articles will cover key events and topics in Addiction Psychiatry from 2023. The Panel of Discussants is comprised of senior AAAP leaders and experts to provide commentary on the articles and engage in audience questions and discussion.

Learning Objectives
  • Increase awareness of key studies in the field of Addiction Psychiatry from the year 2023.
  • Increase working knowledge of key findings from recent cutting edge or important research in Addiction Psychiatry.
  • Discuss the clinical utility and methods for applying the knowledge and findings from key research articles in Addiction Psychiatry.
Keywords / Topics
  • First Party Sesearch
  • Addiction Metrics
  • Medication for Addiction Treatment
  • Emerging Treataments
  • Substance Use Disorder Treatment
Presenters
Carla Marienfeld, MD, DFAPA, FASAM, Chairperson

 

Carla Marienfeld, MD, DFAPA, FASAM is board-certified in psychiatry, addiction psychiatry, and addiction medicine, and she is a Clinical Professor at the University of California San Diego who supports recovery in an evidence based, harm-reduction approach through motivational interviewing and medication treatment. She was named a San Diego Top Doctor in 2021 as Medical Director for the UC San Diego Substance Treatment and Recovery (STAR) program. Her research involves populations with substance use disorders, including pregnant women and the development of their offspring, often using analysis of electronic medical record data. She has authored over three dozen peer reviewed articles, book chapters, practice guidelines, and invited commentaries, and she edited two books: Motivational Interviewing for Clinical Practice and Absolute Addiction Psychiatry Review: An essential board exam study guide. She has a record of grant funding for research and founding the UCSD Addiction Psychiatry Fellowship Program, where she serves as Program Director. She has been highly involved in the education of colleagues and trainees about addiction psychiatry, buprenorphine treatment, and motivational interviewing. Dr. Marienfeld completed a fellowship in addiction psychiatry and residency training in psychiatry at Yale. During her residency, she was chief resident of psychiatry and founded (and later led as junior faculty) the Yale Global Mental Health Program. She earned a medical degree with honors from Baylor College of Medicine in Houston. She is active in many professional organizations, including the American Society of Addiction Medicine, the American Association of Addiction Psychiatry, and the American Psychiatric Association. 

Brian Hurley, MD, MBA, FAPA, DFASAM, Co-Chair

 

Brian Hurley, MD, MBA, FAPA, DFASAM is an addiction psychiatrist and the Medical Director of the Division of Substance Abuse Prevention and Control in the Los Angeles County Department of Public Health and a volunteer assistant clinical professor of addiction medicine in the UCLA Department of Family Medicine. He is the President of the American Society of Addiction Medicine and gives presentations around the world regarding addiction medicine and motivational interviewing. He is a Primary Investigator for an award to the Los Angeles County Department of Public Health from the Substance Abuse Mental Health Services Administration's first Harm Reduction Grant Program. Additionally, he is the grant lead for three Medications for Addiction Treatment Access Points projects funded by the Sierra Health Foundation supporting access to medications for addiction treatment across Los Angeles County. He is a member of the Motivational Interviewing Network of Trainers. 


Joshua D. Lee, MD, MSc, Presenter

 

Joshua D. Lee MD, MSc is a Professor in the Department of Population Health and Dept. Medicine/General Internal Medicine and Clinical Innovation at the NYU Grossman School of Medicine. He is Program Director of the NYU Addiction Medicine Fellowship and Co-Director of DPH’s Section on Tobacco, Alcohol, and Drug Use. He is a clinician researcher focused on alcohol and opioid treatments in primary care and criminal justice populations and leads the NYUGSOM Hub of the NIDA Justice and Community Opioid Innovation Network. He is Science Advisor at Oar Health, an alcohol treatment provider. 

Ismene Petrakis, MD, Discussant

 

Dr. Ismene Petrakis is an addiction psychiatrist , educator and researcher. She serves as the Chief of Mental Health Services at VA Connecticut Healthcare System (VACHS) and Professor of Psychiatry at Yale School of Medicine. She has spent her 3 decade-long entire career in clinical care, research and education in the field of Addiction Psychiatry . Her scholarly work focuses on pharmacologic treatment of patients with alcohol use disorder (AUD) with and without psychiatric comorbidity including post traumatic stress disorder (PTSD). She also has more recently focused on innovative treatments for individuals with opioid use disorder (OUD) . She has had continuous funding from NIH, the VA, DoD and several Foundations. She is also the Director of the Yale Addiction Psychiatry Fellowship and has been invited to serve on numerous national education committees including within the ACGME, the American Academy of Addiction Psychiatry, Research Society on Alcoholism, and the American Board of Addiction Medicine. Many of her mentees are now influential educators and researchers within VA nationally. 


Frances Levin, MD, Discussant



Frances Rudnick Levin, MD is the Kennedy-Leavy Professor of Psychiatry at Columbia University and Chief of the Division on Substance Use Disorders at the New York State Psychiatric Institute. Dr. Levin graduated from Weill Medical College-Cornell University, completed her psychiatric residency at the New York-Presbyterian Hospital (NYPH) and then she graduated from a 2-year combined clinical/research fellowship at the University of Maryland and the Addiction Research Center at the National Institute on Drug Abuse (NIDA). For 22 years, she served as the Director of the Addiction Psychiatry Residency at NYPH and for 19 years, she has been the Director of a T32 NIDA-funded Translational Clinical Research Fellowship. Dr. Levin, working with Columbia University faculty, inaugurated the university-wide Center for Healing of Opioid and Other Substance Use Disorders (CHOSEN) in 2020 and is one of the senior Directors. A critical mission of this Center is to address addiction treatment inequities among minority populations. Dr. Levin is also the Principal Investigator of several NIH grants and is the Medical Director of two SAMHSA-supported grants, the Providers Clinical Support System and the Opioid Response Network which focuses on providing education, mentoring and technical assistance in the areas of prevention, treatment, and recovery. She is dedicated to encouraging addiction training of underrepresented minority predoctoral students through her involvement with a NIDA R25 TRACC (Translational Research Training in Addiction in Underrepresented Groups) and support of a summer training in addictions with CUNY underrepresented minority premedical students. 


Edward Nunes, MD, Discussant

 

Dr. Nunes is Professor of Psychiatry at Columbia University Medical Center and New York State Psychiatric Institute (NYSPI), Multiple PI of the Greater New York Node of the NIDA Clinical Trials Network (CTN), and Co-Director of the CHOSEN Center at Columbia University.  He is a practicing psychiatrist Board Certified in Addiction Psychiatry and Addiction Medicine. He has devoted his career to research on the treatment of opioid, cocaine and other substance use disorders and is nationally and internationally recognized for his work on the evaluation and treatment of co-occurring depression and other psychiatric disorders among patients with substance use disorders and the development of pharmacological and behavioral treatments for substance use disorders, as well as for his work in the CTN testing the effectiveness of behavioral and pharmacological treatments in community-based treatment settings. Dr. Nunes has extensive experience with the design, conduct and analysis of clinical trials of treatments for opioid use disorder, including technology-based interventions and extended-release injections and implants of buprenorphine and naltrexone. 


John A. Renner, Jr., MD, Moderator

 

Renner is a Professor of Psychiatry, at Boston University School of Medicine, and Associate Chief of Psychiatry for the VA Boston Healthcare System. He graduated from Yale University and Case University School of Medicine and Completed His Psychiatric Residency at the Tufts- New England Medical Center. In 1969, Renner Served as a Psychiatrist with the Us Navy in Vietnam, and since 1979 He Has Been Working at the Boston VA in Their Outpatient Addiction Treatment Program. in Addition to His Clinical Activities at the VA, He is Associate Director of the Boston University Medical Center General Psychiatry Residency Program and Director of Their Addiction Psychiatry Residency. Dr. Renner Has Written and Lectured Extensively on the Treatment of Alcoholism and Drug Addiction. He is a Member and Former Chair of the American Psychiatric Association Council on Addiction Psychiatry, Former Chair of the APA Council on Adult Psychiatry, and Former Chair of the APA Expert Advisory Panel on Addiction Psychiatry. In 2018, Renner Co-Edited the 2nd Edition of the APA Handbook of Office-Based Buprenorphine Treatment for Opioid Use Disorder. He is Past-President of the Board of Directors of the AAAP, a Member of the Data Safety Monitoring Board for the Clinical Trials Network of the National Institute on Drug Abuse, a Member of the Clinical Advisory Committee of the Physician Health Service of the Massachusetts Medical Society, a Consultant to the Department of Psychiatry, Massachusetts General Hospital, & a Member of the Faculty of the Harvard Medical School Division on Addictions. 
Summary
Availability: On-Demand
Cost: FREE
Credit Offered:
No Credit Offered
Recommended
 
American Academy of Addiction Psychiatry
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.


 
400 Massasoit Avenue
Suite 307
East Providence, RI 02914
cmecpd@aaap.org



About
Advocacy
Membership
Fellowship
Education and Resources
Training Events

 
Powered By